Perspective Therapeutics
CATX
105 hedge funds and large institutions have $150M invested in Perspective Therapeutics in 2025 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 32 increasing their positions, 30 reducing their positions, and 8 closing their positions.
12,450% more call options, than puts
Call options by funds: $251K | Put options by funds: $2K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
100% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 8
8% more funds holding
Funds holding: 97 → 105 (+8)
1.67% more ownership
Funds ownership: 57.23% → 58.91% (+1.7%)
7% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 30
3% more capital invested
Capital invested by funds: $146M → $150M (+$3.71M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$4.15M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$4.14M |
| 3 |
VC
Vestor Capital
Chicago,
Illinois
|
+$3.54M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$1.67M |
| 5 |
Walleye Capital
New York
|
+$1.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.98M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
-$3.6M |
| 3 |
AAA
Affinity Asset Advisors
New York
|
-$2.73M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$1.79M |
| 5 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
-$1.72M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VWM
101
Vermillion Wealth Management
Rosemount,
Minnesota
| $665 | – | – | – |
|
102
Jones Financial Companies
Des Peres,
Missouri
| $476 | – | – | – |
|
|
ASN
103
Advisory Services Network
Atlanta,
Georgia
| $230 | +$244 | +67 | New |
|
|
WANY
104
Wealthspire Advisors (New York)
New York
| $138 | +$146 | +40 | New |
|
|
SS
105
SBI Securities
Tokyo,
Japan
| $3 | – | – | – |
|
|
106
Marshall Wace
London,
United Kingdom
| – | -$1.79M | -520,707 | Closed |
|
|
VCIM
107
Velan Capital Investment Management
Alpharetta,
Georgia
| – | -$1.72M | -500,000 | Closed |
|
|
SSA
108
Schonfeld Strategic Advisors
New York
| – | -$493K | -143,332 | Closed |
|
|
HS
109
HighVista Strategies
Boston,
Massachusetts
| – | -$476K | -138,350 | Closed |
|
|
EGM
110
Engineers Gate Manager
New York
| – | -$98.8K | -28,708 | Closed |
|
|
GSC
111
Ground Swell Capital
Folly Beach,
South Carolina
| – | -$56.3K | -16,373 | Closed |
|
112
Raymond James Financial
St Petersburg,
Florida
| – | -$6.2K | -1,802 | Closed |
|
|
TSMHT
113
Thurston Springer Miller Herd & Titak
Indianapolis,
Indiana
| – | -$402 | -117 | Closed |
|
CATX Hedge Fund Activity: Q3 2025 in Review
105 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Perspective Therapeutics (CATX) for Q3 2025, worth a combined $150M — up 2.5% from $146M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new CATX positions and 8 closed out — a net gain of 8 holders — while 32 added to existing stakes and 30 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $4.15M. The largest seller was Fidelity Investments, cutting an estimated $3.98M.
- 105 institutional investors held Perspective Therapeutics (CATX) as of Q3 2025, up from 97 in Q2 2025.
- Funds reported $150M of Perspective Therapeutics stock for Q3 2025, up 2.5% quarter-over-quarter.
- 16 funds opened new Perspective Therapeutics positions in Q3 2025 and 8 closed out, a net change of +8 holders.
- The largest Perspective Therapeutics buyer in Q3 2025 was Morgan Stanley, an estimated $4.15M added.
- The largest Perspective Therapeutics seller in Q3 2025 was Fidelity Investments, an estimated $3.98M sold.
Based on aggregated 13F filings for Q3 2025.